Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Middleton

Showing results (441-450 of 522) with videos related to

Pageof 53
Sort By:
Nature Medicine|February 12, 2020
Peripheral CD8<sup>+</sup> T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanomaBenjamin P Fairfax, Chelsea A Taylor, Robert A Watson, et al.
BJUI Compass|April 7, 2023
PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancerVictoria K Woodcock, Ji-Li Chen, Karin Purshouse, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2023
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanomaDrew W Rasco, Theresa Medina, Pippa Corrie, et al.
The Lancet. Oncology|July 14, 2018
Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trialPaul C Lyon, Michael D Gray, Christophoros Mannaris, et al.
British Journal of Cancer|November 20, 1998
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanomaM R Middleton, J M Lunn, C Morris, et al.
Targeted Oncology|May 13, 2016
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor OlaparibJ Mateo, V Moreno, A Gupta, et al.
Journal of Dairy Science|August 5, 2022
Invited review: Selective use of antimicrobials in dairy cattle at drying-offKayley D McCubbin, Ellen de Jong, Theo J G M Lam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1E Ruth Plummer, Mark R Middleton, Christopher Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanomaMalcolm Ranson, Peter Hersey, Damien Thompson, et al.
Cancers|April 30, 2021
Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic CancerShivan Sivakumar, Enas Abu-Shah, David J Ahern, et al.
Pageof 53

Showing results (441-450 of 522) with videos related to

Sort By:
Pageof 53
Nature Medicine|February 12, 2020
Peripheral CD8<sup>+</sup> T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanomaBenjamin P Fairfax, Chelsea A Taylor, Robert A Watson, et al.
BJUI Compass|April 7, 2023
PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancerVictoria K Woodcock, Ji-Li Chen, Karin Purshouse, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2023
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanomaDrew W Rasco, Theresa Medina, Pippa Corrie, et al.
The Lancet. Oncology|July 14, 2018
Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trialPaul C Lyon, Michael D Gray, Christophoros Mannaris, et al.
British Journal of Cancer|November 20, 1998
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanomaM R Middleton, J M Lunn, C Morris, et al.
Targeted Oncology|May 13, 2016
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor OlaparibJ Mateo, V Moreno, A Gupta, et al.
Journal of Dairy Science|August 5, 2022
Invited review: Selective use of antimicrobials in dairy cattle at drying-offKayley D McCubbin, Ellen de Jong, Theo J G M Lam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1E Ruth Plummer, Mark R Middleton, Christopher Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanomaMalcolm Ranson, Peter Hersey, Damien Thompson, et al.
Cancers|April 30, 2021
Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic CancerShivan Sivakumar, Enas Abu-Shah, David J Ahern, et al.
Pageof 53